Myriad Genetics (NASDAQ:MYGN) Releases FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.070-0.110 for the period, compared to the consensus earnings per share estimate of 0.090. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $883.1 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Myriad Genetics Trading Down 4.8 %

Shares of MYGN stock opened at $12.52 on Friday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics has a 52 week low of $12.17 and a 52 week high of $29.30. The stock has a fifty day moving average of $14.78 and a 200 day moving average of $21.97.

Analysts Set New Price Targets

A number of research firms have weighed in on MYGN. Stephens reiterated an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a report on Thursday. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $30.00 to $21.00 in a report on Monday, December 9th. UBS Group assumed coverage on Myriad Genetics in a research report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective for the company. Morgan Stanley decreased their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, November 18th. Finally, Bank of America cut their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $23.92.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.